Form 4 for TBPH Theravance Biopharma, Inc.
Accepted 2025-12-01 00:00:00 ET · period of report 2025-11-26 · accession 0001256230-25-000009 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-12-01 | 2025-11-26 | TBPH | BROSHY ERAN | Dir | S - Sale | $20.00 | -29.5K | 60.2K | -33% | -$590.0K |
| D | 2025-12-01 | 2025-11-26 | TBPH | BROSHY ERAN | Dir | M - OptEx | $10.15 | +14.0K | 81.7K | +21% | +$142.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2025-11-26 | S | D | 15,501 | $20.00 | 44,703 | D | — | — | (F2) The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024. |
| 2 | Common | Ordinary Shares | 2025-11-26 | S | D | 14,000 | $20.00 | 60,204 | D | — | — | (F1) The reporting person exercised stock options to acquire 14,000 Ordinary Shares and sold all such shares on the same day in a broker-assisted transaction. No shares were withheld for taxes. The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024. |
| 3 | Derivative | Share Option (Right to Buy) | 2025-11-26 | M | A | 14,000 | $10.15 | 81,749 | D | $10.15 · — to 2032-04-25 | 14,000 Ordinary Shares | (F4) Reflects solely exercisable, vested Share Options following reported transaction. (F3) This Share Option was fully vested and exercisable (having vested as to 1/12th of the shares subject to the option upon completion of each continuous month of service following the original grant date and any remaining unvested shares vesting on the date of the next annual meeting of the company's shareholders provided continuous service through such date). |